All In Biotech

Drug Trial Radar · NCT06574009

Better Options for Chronic Cancer Pain

Better Options for Chronic Cancer Pain: a SMART Study

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

294

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

Apr 1, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Aug 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This proposal is relevant to the 240,000 cancer survivors who continue to use opioids long after they have successfully completed treatment for cancer at the VHA, placing them at risk of opioid addiction and overdose, and other opioid-related problems. Yet, there are no programs at the VHA to help them find alternatives to opioids, nor evidence to inform the choice of interventions. This study will meet these needs by examining four interventions that are effective at reducing opioid use in patients with chronic musculoskeletal pain but have yet to be tested in cancer survivors on long term opioid therapy. The proposed work is relevant to the VHA Pain Office's mission to provide Veterans better pain management while limiting the risks of long-term opioid therapy and it aligns with VHA Research and Development's priority to examine clinical interventions for tapering opioids. Successful completion this project will keep VHA at the forefront of the battle against the opioid epidemic with a strategy that may be adapted to address the same needs in non-Veterans.

Conditions

  • Chronic Pain
  • Cancer Survivor
  • Opioid Dependence

Interventions

  • Multimodal pain careBehavioral

    Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage

  • Medication optimizationDrug

    Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.

  • Buprenorphine rotationDevice

    Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol

  • Opioid taperingOther

    Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Opioid dose reduction + Pain response (binary: yes/no)Time frame: 9 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Richard L. Roudebush VA Medical Center, Indianapolis, IN

    Indianapolis, Indiana · Not yet recruiting

  • VA Ann Arbor Healthcare System, Ann Arbor, MI

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.